September 29, 2017 / 5:24 AM / a year ago

Roche's Perjeta regimen gets FDA priority review in breast cancer

ZURICH, Sept 29 (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.

The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.

A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines (Reporting by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below